Monday, September 01, 2014 8:29:10 PM
If we get EbolaCide efficacy in-vivo tests completed successfully I expect NanoViricides, Inc. to join Glaxo Smith Kline and Tekmira in a race, through clinical trials, and to produce Ebola antiviral drugs.
About vaccines...
http://www.internano.org/content/view/541/292/
Glaxo Smith Kline and Tekmira are going to enter their respective Ebola vaccine Clinical Trials for safety however, if vaccines "usually fail with the emergence of mutated viruses" then what??? Who is going to keep tabs on efficacy for these two vaccine makers or us, if we join in the race? Hopefully they have a plan because you just don't want to throw more money at a deadly problem as Ebola.
Related:
As Ebola Outbreak Expands, These Experimental Drugs Could See Action
http://www.forbes.com/sites/scottgottlieb/2014/08/18/as-the-ebola-outbreak-expands-these-experimental-drugs-could-see-action/
Regulatory Explainer: What You Need to Know About the Regulation of Ebola Treatments
http://www.raps.org/Regulatory-Focus/News/2014/08/07/19977/Regulatory-Explainer-What-You-Need-to-Know-About-the-Regulation-of-Ebola-Treatments/
How the health system would respond if Ebola spread on U.S. soil
http://www.advisory.com/daily-briefing/2014/08/14/how-the-health-system-would-respond-if-ebola-spread-on-us-soil
==============================================
Pushing the rule of law aside and making decisions based on politics --- Crony Capitalism
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM